Published in Gene Therapy Weekly, January 15th, 2004
These classes of adenoviral vectors are particularly important in the commercial production of adenovirus vectors, and in a number of emerging cancer and gene therapy fields, such as the use of oncolytic viruses to kill cancer cells. The patent claims of U.S. 6,630,344 broadly cover adenoviruses engineered to control tissue replication through the use of tissue-specific control elements.
Dr. David L. Parker, Introgen's vice president for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.